Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Cancer
Interventions: cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis; Biological · Genetic · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Diabetic Foot Ulcer, Surgical Wound
Interventions: Natrox® Oxygen Wound Therapy; Device
Lead sponsor: Inotec AMD Limited; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more

Conditions: HIV-1 Infection
Interventions: depo-medroxyprogesterone acetate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 13 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 7 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2033
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anterior Uveitis
Interventions: Dexamethasone; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope; Device
Lead sponsor: The Geneva Foundation; Other
Eligibility: 18 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Skin Diseases, Infectious, Skin Diseases, Bacterial
Interventions: TR-701 200 mg, TR-701 300 mg, TR-701 400 mg; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Dothan, Alabama • Chula Vista, California • Long Beach, California + 9 more

Conditions: Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Betalutin; Drug
Lead sponsor: Nordic Nanovector; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Diego, California • San Francisco, California • Miami, Florida

Conditions: Hepatitis C
Interventions: Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Beverly Hills, California • Baltimore, Maryland

Conditions: COVID-19
Interventions: Hydroxychloroquine, Azithromycin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Mitoguazone; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions: Semaglutide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: Up to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 2 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: HIV Infections, Lymphoma, AIDS-Related
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End Stage Renal Disease, Hepatitis C
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Raltegravir (MK-0518), Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more

Conditions: HIV
Interventions: TMC125, Darunavir; Ritonavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: RSV Infection
Interventions: EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Human Immunodeficiency Virus
Interventions: Placebo Vaginal Ring, Condom; Combination Product · Device
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Berkeley, California • Los Angeles, California

Conditions: Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions: Molgramostim nebulizer solution, PARI eFlow nebulizer system; Drug · Device
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more

Conditions: Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections, Sexual Behavior
Interventions: IMARA for Black Male Caregivers and Girls Empowerment, Time-matched control program; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 13 Years and older
Enrollment: 612 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HAART Non-Adherence, HIV, HIV Infections
Interventions: Cell Phone Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 24 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 2 more

Search by objective public record fields.

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers

Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients

A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

Cell Phone Reminders Intervention